## Eva Szabo

## List of Publications by Citations

Source: https://exaly.com/author-pdf/9044005/eva-szabo-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10	320	5	11
papers	citations	h-index	g-index
11	397 ext. citations	24.7	2.02
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
10	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancera plan to move forward. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 3661-97	12.9	235
9	Molecular cancer prevention: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2015</b> , 65, 345-83	220.7	51
8	A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index. <i>Cancer Prevention Research</i> , <b>2020</b> , 13, 203-212	3.2	10
7	Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. <i>Gut</i> , <b>2021</b> , 70, 555-566	19.2	10
6	Cancer Prevention in Primary Care: Perception of Importance, Recognition of Risk Factors and Prescribing Behaviors. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 723-732	2.4	6
5	Acceptability of Localized Cancer Risk Reduction Interventions Among Individuals at Average or High Risk for Cancer. <i>Cancer Prevention Research</i> , <b>2019</b> , 12, 271-282	3.2	5
4	Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians. <i>Cancer Prevention Research</i> , <b>2021</b> , 14, 205-214	3.2	2
3	Report from an NCI Roundtable: Cancer Prevention in Primary Care <i>Cancer Prevention Research</i> , <b>2022</b> , 15, 273-278	3.2	1
2	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.  Journal of Cancer Prevention, <b>2021</b> , 26, 71-82	3	O
1	Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs <i>Cancer Prevention Research</i> , <b>2022</b> , 15, 279-284	3.2	О